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Abstract
The CRISPR-Cas system is a promising form of gene editing, especially for the agriculture
industry. The ability to make single-nucleotide edits within a gene of interest, without the need to
introduce foreign DNA, is a powerful tool for designing healthier and more efficient crops and
food animals. This system provides opportunity for increased nutritional value, decreased food
waste, and more economically and environmentally sustainable food production. Though this
biotechnology is facing mechanistic limitations due to off-target effects and inefficient
homology-directed repair, vast improvements have already been made to improve its efficacy.
The CRISPR-Cas system is already the most advanced form of gene editing available. This paper
also discusses the regulation of gene-edited agricultural products. While countries such as
Australia recognize that gene editing cannot be distinguished from natural mutations and
evolution, other entities such as the European Union treat these food products as genetically
modified organisms, which subjects them to strict regulatory processes and testing. These
conflicting policies will lead to novel effects on international trade. Though the CRISPR-Cas
system is facing many mechanistic and regulatory challenges, and significant factors such as the
public’s opinion still need to be considered, it still has great potential to improve the global
agriculture industry and provide a more sustainable future.
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Introduction
Gene editing, which is a field of biotechnology that has only existed since the late 1900s,
has grown dramatically in efficacy and range of applications. Gene editing is the ability to
modify the DNA within a living organism through insertion, deletion, and substitution events.
Since its introduction, this novel practice held the potential to safely alter DNA in a targeted
manner. This differed from previous engineering practices such as genetic modification because
it does not require the introduction of foreign DNA. Gene engineering takes advantage of
naturally occurring cellular processes and uses them for directed changes to the genetic material.
The major components of gene editing are site-specific nucleases (SSNs), doublestranded DNA breaks, and the repair of these breaks (Lino et al., 2018). The two potential repair
mechanisms are non-homologous end joining (NHEJ) and homology-directed repair (HDR)
(Lino et al., 2018). The former is the most common type of repair because it can occur at any
stage in the cell cycle, and simply re-ligates the strands directly, or with small insertions or
deletions (Hefferin & Tomkinson, 2005). On the other hand, HDR involves a template for repair,
and is a much more precise mechanism (Lino et al., 2018). However, it only occurs when there is
an extra copy of the cell DNA present to be used as the template, which is during the S and G2
phases of cell growth (Lino et al., 2018). Homology-directed repair is especially important
because it provides an avenue for more desirable gene products.
It is the SSN involved and mechanism by which the repair occurs that determines the
gene products resulting from a double-stranded break (Lino et al., 2018). NHEJ can only lead to
gene knockout, resulting from frameshifts through insertion and deletion events, or gene
deletion, through the use of paired SSNs on either side of the gene of interest (Lino et al., 2018).
In contrast, with its use of genetic templates, HDR can produce precise gene corrections or
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additions (Lino et al., 2018). Multiple site-specific nucleases can be used to cut DNA and obtain
any of these gene products. Zinc finger nucleases (ZFNs), for example, were introduced in 2002,
but they had limitations in regards to high-affinity binding and sequence selection (Lino et al.,
2018). Transcription activator-like effector nucleases (TALENs) made improvements to this
system, and are less likely to produce off-target cutting (Lino et al., 2018). However, TALENs
are much larger than ZFNs, and therefore more difficult to introduce into living cells (Lino et al.,
2018). Both of these systems utilize proteins with a DNA-binding domain that has been
specifically engineered to match the sequence of interest (Bortesi & Fischer, 2015). The most
promising SSN yet is the CRISPR-Cas system.

CRISPR-Cas System
CRISPR stands for clustered regulatory interspaced short palindromic repeat; essentially,
it is a repetitive DNA sequence found in nature. Though this type of sequence was initially
discovered in 1987 in Escherichia coli, and was found in many other bacterial and even archaeal
species over the years, it was not until the early 2000s that scientists understood the important
immune system role it played (Ishino et al., 2018). Around this time, it was also discovered that
some genes encoding DNA repair proteins were closely paired with CRISPR, and were thus
named CRISPR-associated (Cas) genes (Ishino et al., 2018). These components work as an
acquired immune response in bacterial cells, by recognizing and attacking invading pathogens
(Ishino et al., 2018). The system recognizes pathogens due to the spacers in the CRISPR
sequence that were captured from invading microorganisms and thus are homologous to the
invaders (Ishino et al., 2018). These spacers are transcribed into short crRNA molecules, which
can then interact with a Cas protein to form an endonuclease complex (Ishino et al., 2018). The
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complex uses the crRNA as a guide to recognize invaders and attack them (Ishino et al., 2018). It
is important to note that the matches between the CRISPR-Cas system and the pathogen
sequences do not need to be exact. In fact, the system has evolved to respond with flexibility;
that is, the cell can protect itself against the initial pathogen and its relatives. This means the cell
does not need to store as many homologous spacers, and it can be protected against invaders it
has not necessarily encountered yet.
Though Cas proteins constitute a whole family of endonucleases, only certain members
are useful for gene editing purposes (Ishino et al., 2018). The Type II system is most commonly
used due to its relative simplicity and ease of manipulation (Ishino et al., 2018). More
specifically, the Cas9 protein has been found to be ideal in gene editing, and has been used in a
variety of genetic manipulations, including bacterial, plant, and human applications. The system
has also been optimized for gene editing through the use of a guide RNA (gRNA) (Lino et al.,
2018). This gRNA is used in place of the crRNA of the natural system, and can be designed with
relative ease to be homologous to the gene target sequence (Lino et al., 2018).

Human Health Applications
These advances in gene editing and the CRISPR-Cas system are significant due to the
impacts in many fields, ranging from human health to food production. In the United States and
some other major countries, CRISPR systems are entering their first human clinical trials to treat
fatal diseases, by applying the editing technology in somatic tissues. The first applications of the
CRISPR-Cas system in human disease treatment focused on blood diseases, because of the
ability to isolate and target haematopoietic stem and progenitor cells (HSPCs) (Dever et al.,
2016). Some early studies aimed to treat sickle cell disease, as it is caused by a mutation in the
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globin gene (Dever et al., 2016). If scientists are able to correct the mutation, then millions of
people could be successfully treated (Dever et al., 2016). These studies produced promising
results. For one, cytotoxic side effects and off-target frequency decreased significantly when
introducing the system as a ribonucleoprotein (RNP) complex, as opposed to an mRNA (Dever
et al., 2016). Using the RNP complex, the desired mutation was detected in an average of 29% of
the HSPCs, and the on to off-target activity ratio was about 25 to 1 (Dever et al., 2016). Though
the results were not perfect, and the system was not ready for human-implementation at the time,
this study provided important information regarding methods of delivery, frequency of nondesirable effects, and potential improvements to the technology moving forward (Dever et al.,
2016).
More recently, researchers have discussed the potential use of CRISPR-Cas for treating
cystic fibrosis, a lung disease caused by a mutant CFTR allele (Hodges & Conlon, 2019). This
would be very advantageous for patients due to potential as a disease correction, as opposed to
ongoing treatment, which would also help lower overall medical costs (Hodges & Conlon, 2019).
Cystic fibrosis is a more difficult disease to treat with this biotechnology due to challenges in
delivering the system to this less-accessible tissue (Hodges & Conlon, 2019). In order to achieve
the desired, one-time treatment, basal stem cells in the lungs would need to be targeted (Hodges
& Conlon, 2019). These are not only more difficult to reach via airways than apical cells, but
also cystic fibrosis patients exhibit “more abundant, thicker mucus, infection and inflammation”
that make it even harder to deliver the CRISPR-Cas system (Hodges & Conlon, 2019). Hodges
and Conlon (2019), provide an analysis of potential solutions to this problem. They emphasize
the need to use animal models, and build upon current delivery systems that have showed limited
success, such as adenovirus co-administered with surfactant (Hodges & Conlon, 2019). Despite
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the obstacles that this treatment will face before it can be implemented, researchers remain
hopeful that a successful system can be developed within the next few years (Hodges & Conlon,
2019).
Studies and analyses such as these were very important to the development of the
CRISPR-Cas system for human use. As of April 2019, companies such as Vertex
Pharmaceuticals Incorporated and CRISPR Therapeutics announced that they have begun FDAapproved clinical trials for two blood disorders: beta-thalassemia and sickle-cell disease
(“CRISPR enters its first human clinical trials,” 2019). In addition, the University of
Pennsylvania, and some labs in China, are currently using T cells programmed with CRISPR to
treat patients with reoccurring cancers (“CRISPR enters its first human clinical trials,” 2019). It
is important to note a number of caveats concerning the current use of CRISPR technology in
human applications. For one, the people and diseases being treated are mostly using CRISPRCas as a final treatment option (“CRISPR enters its first human clinical trials,” 2019). Meaning,
these patients have exhausted other, more common methods that have been unsuccessful in
treating their disease (“CRISPR enters its first human clinical trials,” 2019). Also, the CRISPRCas system is currently being used only to treat somatic tissues (“CRISPR enters its first human
clinical trials,” 2019). In other words, this technology is not being implemented in embryonic
stem cells. This helps reduce some of the risks associated with off-target effects, as the cells
containing mutations, both desired and incidental, will not go on to produce an entire cell
population with potentially deleterious effects (“CRISPR enters its first human clinical trials,”
2019). Even while considering these conditions, many researchers are very hopeful about future
human disease applications such as cystic fibrosis and Duchenne muscular dystrophy (“CRISPR
enters its first human clinical trials,” 2019).

Laliberte 8
Human disease studies faced a major set-back, however, in 2018 when Dr. He Jiankui
announced he had developed the first ever gene-edited babies (Cyranoski, 2020). Dr. He’s work
is controversial for a number of reasons. For one, the goal of his experiment was to make the
human babies less susceptible to inheriting HIV from their parents, which is unnecessary due to
precautions that can already be taken with existing technologies (Cyranoski, 2020). The target
gene was CCR5, and though it is known to be associated with HIV, it is not effective in treating
all strains, and many researchers did not believe that Dr. He and his team took the necessary
precautions to prevent off-target effects (Cyranoski, 2020). In addition, this lab disregarded the
general worldwide scientific view that no experiments should be done on human embryos for
reproductive purposes (Cyranoski, 2020). As a result of his actions, Dr. He was recently
sentenced to three years in prison, a 3 million yuan (US$430,000) fine, and a ban from working
with human reproductive technology for “illegal medical practice” (Cyranoski, 2020). Two of his
colleagues, Dr. Zhang Renli and Dr. Qin Jinzhou, are the only other scientists to face
consequences so far (Cyranoski, 2020). Not only did Dr. He shock the scientific community, he
also sparked a reaction from the general public (Cyranoski, 2020). This experiment brought the
CRISPR-Cas system to the forefront of news for the first time, and caused public backlash
(Cyranoski, 2020). Many people became concerned with the concept of designer babies, which
are embryos that “have been genetically enhanced, rather than merely correcting disease-causing
mutations” (Ledford, 2017). Besides the bioethical issues of designer babies, they also represent
a technology that would only be available to the exclusive few that could afford it, which brings
in additional socioeconomic problems. As a result of the association between CRISPR human
applications and these controversial fields, many researchers worry that the negative opinions
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surrounding this work will have damaging effects on funding and regulation of this
biotechnology moving forward (Cyranoski, 2020).

Agricultural Applications
Such issues should not affect the agricultural applications of the CRISPR-Cas system,
because it has only been implemented in the somatic tissues of plants. While CRISPR has only
just entered human clinical trials, large companies have been working to introduce CRISPR gene
editing to the food industry for many years. This is an important step for agriculture because it
provides an alternative to genetic modification. Genetic modification not only faced serious
public backlash due to its use of foreign DNA to introduce novel characteristics into crops, it
also suffered from strict regulation. Gene editing has the potential to both evade strict regulation
and improve the effectiveness of food production (Gao, 2018). Gene editing in plants is viewed
by most scientists as a breeding mechanism (Gao, 2018). That is to say, the insertion, deletion,
and substitution events that occur as a result of the CRISPR system could occur in nature;
scientists are merely speeding up evolution by more efficiently selecting advantageous traits
(Gao, 2018). For this reason, researchers argue that it would be very difficult to distinguish
CRISPR-edited products from more typical plant breeding techniques, and therefore would be a
challenge to regulate these products (Gao, 2018). There are several other important implications
of the use of CRISPR-Cas in agriculture. For one, this system can be used to prevent disease by
targeting risk genes for DSBs followed by NHEJ and more complex applications using HDR
(Gao, 2018).
Most of all, CRISPR gene editing techniques hold the potential for sustainable agriculture
(Gao, 2018). The world’s population is growing at a rapid rate, and there are currently many
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regions without a consistent supply of food. Whether due to climate and environmental factors,
or economic limitations, these regions are unable to successfully produce the food necessary for
the people there. Gene editing, especially the CRISPR-Cas system, can help solve this problem
in a number of ways. Crops can be made more weather and pest resistant, which will allow them
to grow in a wider range of environments and climate conditions (Gao, 2018). CRISPR is unique
in that it can also provide the ability to target evolution and produce new traits that are very
advantageous (Gao, 2018). For example, nitrogen fixation is currently only present in legumes,
but CRISPR could help researchers drive the evolutionary process to produce this trait in other
organisms (Gao, 2018). In addition, shelf-life can be improved by targeting the genes responsible
for ripening, leading to reduced waste and more efficient use of the existing food supply.
CRISPR technologies also have the potential to improve nutritional value of food crops by
enhancing the genes responsible for the production of key vitamins and essential amino acids,
and knocking out those responsible for decreased absorption (Rajendran et al., 2015). Other
applications include the silencing of genes encoding common allergens such as gluten and βlactoglobulin (Rajendran et al., 2015). According to Gao (2018), agriculture can also be made
more sustainable because of “the relatively low cost and ease of use of CRISPR tools are
spurring innovative research in academia and in companies of all sizes”. The fact that CRISPR
technologies can be used by both large corporations and relatively small farming operations is
significant because it means that research can be done at all levels of production, which will
promote the economic sustainability of the industry. This is a major difference between most
human applications and the agricultural uses of CRISPR gene editing. The human treatment
options, even those that are not embryonic, are most likely going to be expensive and relatively
exclusive. On the other hand, agricultural applications can be applied at various scales of
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production, from individual farmers, to conglomerates. Overall, the impacts of CRISPR-Cas
technologies are significant in a broad range of ways, and the field has yet to see the full
potential of such advances.
Compared to previous gene editing methods, the CRISPR-Cas system has several unique
advantages. The CRISPR-Cas9 complex does not require any protein engineering like ZFNs and
TALENs (Bortesi & Fischer, 2015). Instead, researchers can just manipulate the gRNA
sequence, which is more versatile, and relatively easy to work with (Bortesi & Fischer, 2015). It
was also discovered in human cells that this system has the ability to cleave methylated DNA
(Bortesi & Fischer, 2015). If this ability is also present in regards to plant genomes, this would
confer a significant advantage over ZFNs and TALENs, as plants have a large number of
methylation sites (Bortesi & Fischer, 2015). Lastly, the CRISPR-Cas system is able to introduce
double-stranded breaks at multiple sites at the same time (Bortesi & Fischer, 2015). This process,
called multiplexing, is important because it allows for large engineered inversions, and makes it
possible to edit multiple genes at once (Bortesi & Fischer, 2015). Though ZFNs and TALENs
can also achieve this, it takes significantly more time and effort, as these systems require
individually designed proteins at each target site (Bortesi & Fischer, 2015). Meanwhile, this
ability seems more inherent to the CRISPR-Cas system due to the natural format containing
repeating spacer regions (Cong et al., 2013).

Mechanistic Limitations
Despite the unique capabilities of this gene editing system, there are still a number of
important limitations to consider. The mechanisms of this technology are not yet fully
developed, and still require much improvement in regards to efficacy. As discussed earlier, non-
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homologous end joining is the dominant form of DSB repair. This means that when researchers
are attempting to take advantage of the HDR mechanism, NHEJ often still occurs because it is
more rapid and prevalent in the cell (Gao, 2018). As a result, large amounts of template DNA are
required to attempt to override this natural process (Gao, 2018). In order to effectively use the
CRISPR-Cas system, improvements must be made to the efficiency of HDR and achieving the
mutations of interest. One potential solution is to silence the mechanisms of NHEJ, by targeting
the proteins involved in this process (Lino et al., 2018). Though some success was achieved,
there still remain concerns about the cytotoxic side-effects of reducing NHEJ (Lino et al., 2018).
As mentioned, the CRISPR system evolved to have flexibility in binding, so as to attack
pathogens it had previously encountered, and any related sequences. This ability for mismatch in
the homologous sequences is advantageous for cell immunity purpose in nature, but causes
problems for gene editing applications (Lino et al., 2018). Decreased sequence specificity can
cause difficulties in precise binding to the target gene, and can also lead off-target binding (Lino
et al., 2018). Off-target effects are a major concern due to potential gene disruption and
translocation events during the repair process. In humans, this could lead to activation of
oncogenes or silencing of tumor suppressor genes, among other effects, and so CRISPR-Cas
gene editing would therefore be too risky to implement (Cho et al., 2014). As a result, significant
efforts are being made to improve gRNA design and Cas9 efficiency (Lino et al., 2018). For
example, Cho et al. (2014) found that pairing nuclease and nickase (single-strand break proteins)
activity lead to increased efficiency for target genes, and decrease negative off-target effects.
This was a significant improvement to the efficacy of the system as a whole, but it also makes
the process more difficult to execute, as two highly effective gRNA molecules are necessary for
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success (Cho et al., 2014). Overall, the CRISPR-Cas system has advanced substantially,
especially in the last 10 years, but there is still a lot of room for improvements.
Another solution that has shown promising results is the use of alternative Cas proteins.
For example, one group tested the efficacy of using Cas12b as the endonuclease (Teng et al.,
2018). This system, which is dual-RNA-guided, is used for a wide range of purposes in
mammalian genome engineering, and has potential uses for both single and multiplex editing
(Teng et al., 2018). The experiment here produced successful mutation at the gene of interest,
and also showed zero off-target site effects, out of the 2657 potential sites that differed from the
target sequence by five or less nucleotide mismatches (Teng et al., 2018). These results indicate
not only that this particular system could be very useful, but also that the Cas proteins may be
able to be modified to obtain these high levels of specificity (Teng et al., 2018).

Regulatory Limitations
Besides mechanistic drawbacks with this system, CRISPR could also face regulatory
issues in agriculture. Though gene editing is more likely to avoid government regulation than
genetic modification, there are still concerns, especially for applications that use gRNA (as some
consider it to be foreign genetic material). Recently, many major countries have released
decisions and updated regulatory frameworks regarding how they plan to regulate CRISPRediting crops and food products. In March of 2018, the United States Department of Agriculture
released the following statement:
Under its biotechnology regulations, USDA does not regulate or have any plans to
regulate plants that could otherwise have been developed through traditional breeding
techniques … The newest of these methods, such as genome editing, expand traditional
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plant breeding tools because they can introduce new plant traits more quickly and
precisely, potentially saving years or even decades in bringing needed new varieties to
farmers. (Secretary Perdue Issues USDA Statement on Plant Breeding Innovation, n.d.)
Sonny Perdue, the Secretary of Agriculture, went on to reassure the public that the USDA would
remain vigilant in its regulation of crops, but it would not interfere where there is no risk
(Secretary Perdue Issues USDA Statement on Plant Breeding Innovation, n.d.). Besides the fact
that gene editing is often indistinguishable from traditional breeding methods, the Secretary also
cited other reasons to allow this innovative technology, such as improved disease and weather
resistance, and increased availability of healthy and affordable food, all of which were major
advantages discussed earlier (Secretary Perdue Issues USDA Statement on Plant Breeding
Innovation, n.d.). Despite the USDA’s strong stance of support, United States regulation of gene
editing technologies is also dependent on the Food and Drug Administration and the
Environmental Protection Agency. These three organizations work in tandem with the
Coordinated Framework for the Regulation of Biotechnology to regulate gene editing in all its
applications.
In contrast to the USDA’s statement, the FDA released a draft for procedures entitled
“Regulation of Intentionally Altered Genomic DNA in Animals”. Under the guidelines outlined
in this draft, any animals whose genomes were intentionally altered using any modern
biotechnology are subject to regulation as a “new animal drug” (CVM GFI #187 Regulation of
Intentionally Altered Genomic DNA in Animals, 2017). This includes all gene editing techniques,
even if the resulting alteration could have occurred in nature, such as insertion or deletion events
resulting from CRISPR-Cas activity (CVM GFI #187 Regulation of Intentionally Altered
Genomic DNA in Animals, 2017). This decision has prompted backlash in the scientific
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community, because many researchers believe that these technologies do not pose unreasonable
risk, and therefore should not be subjected to such strict regulations (Eenennaam et al., 2019).
Eenennaam et al. (2019) also argue that this new policy directly contradicts previous regulatory
procedures which stipulated that products should be assessed because of the risk they pose, not
because of a particular technique used to create them.
These regulations have already caused extensive problems for the development of gene
edited animals in the United States (Eenennaam et al., 2019). Not only have no transgenic food
animals reached consumers, but those that are ready for market are incurring extensive
regulatory costs, which is harming the CRISPR-Cas system’s ability to be an affordable method
for food production (Eenennaam et al., 2019). Additionally, even the AquAdvantage salmon,
which was developed in 1989 and did not receive FDA approval until 2015, has not been made
available to United States consumers (Eenennaam et al., 2019). This food animal product,
developed in Canada, has been blocked from import and sale in the U.S. until a program is
developed for informing consumers they are buying bioengineered products (Eenennaam et al.,
2019).
So far, no official progress has been made in regards to labeling such food animal
products. In 2018, though, the FDA releasing a statement that manufacturers could voluntarily
label their products as containing or not containing gene-edited products using phrases such as
“not genetically engineered,” “not bioengineered,” or “not genetically modified through the use
of modern biotechnology” (Center for Food Safety and Applied Nutrition, 2018). Additionally,
despite the draft policies previously released, this statement said the FDA “is not aware of any
information showing that foods derived from genetically engineered plants, as a class, differ
from other foods in any meaningful or uniform way. These foods also don’t present different or
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greater safety concerns than their non-genetically engineered counterparts.” (Center for Food
Safety and Applied Nutrition, 2018) These seemingly contradicting ideas make it difficult to
predict the FDA’s official policies regarding gene editing in agriculture. The only concrete
labelling policy currently in effect is the requirement to label any gene-edited products that have
“compositional differences resulted in material changes” (Center for Food Safety and Applied
Nutrition, 2018). This refers to foods where the nutrition value may have changed, such as high
oleic soybean oil and laurate canola oil (Center for Food Safety and Applied Nutrition, 2018).
Eenennaam et al. (2019) also claims that titling these gene editing food animals as
“drugs” may also cause public outcry similar to that in response to genetically modified animals.
This would lead to even more delays to gene edited food animal integration into the market, and
be very detrimental to gene editing research and applications. Despite these harsh restrictions, it
is still important to consider that the FDA’s regulations were released in 2017 as a draft, and
there is yet to be any official policies put into practice.

International Regulations
Other leading political entities, such as the European Union, Australia, and China, have
also made key decisions regarding the regulation of genome-edited agricultural products. The
EU, in particular, is known for its strict oversight of such biotechnology practices. This history of
harsh regulations is a result of European consumers’ lack of trust in the government to enforce
food safety, stemming from inadequate response to issues such as mad cow disease
(Accountability Office, 2001). Though the inadequate response had nothing to do with gene
editing or biotechnology food, European consumers became wary of new foods (Accountability
Office, 2001). In July of 2018, the EU Court of Justice released its decision to regulate
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“organisms obtained by mutagenesis” as genetically modified organisms (Organisms obtained by
mutagenesis are GMOs and are, in principle, subject to the obligations laid down by the GMO
Directive, 2018). This decision, which is similar to the draft procedures of the FDA in the United
States, asserts that all gene-edited organisms will be regulated to the same, strict degree as
GMOs (Organisms obtained by mutagenesis are GMOs and are, in principle, subject to the
obligations laid down by the GMO Directive, 2018). Conversely, the Australian Office of the
Gene Technology Regulator took a more lenient approach to regulating CRISPR and other gene
editing technologies. In fact, most CRISPR methods will require no government approval for use
in plants and animals (Overview of amendments to the Gene Technology Regulations 2001,
2019). With the updates to their regulatory system, the Australian government will only restrict
technologies that use nucleases from transgenes integrated into the genome, not the nucleases
expressed from a transient transgene or those inserted directly (Overview of amendments to the
Gene Technology Regulations 2001, 2019). Though the major political powers have varying
regulatory practices, this area of CRISPR technologies could prove to be challenging in the
evolution of the field.
Another important nation to consider is China, as it leads to world in number of CRISPRrelated agricultural papers it publishes, twice as many as the United States, which is in the
runner-up (Cohen, 2019). One of the reasons China is a leader in this field is Dr. Gao Caixia,
who in 2013 was the first to use CRISPR to modify a plant genome (Cohen, 2019). She and her
team are currently working on many crop projects, ranging from hardy tomatoes and aromatic
rice, to fungus-resistant wheat and herbicide-resistant corn (Cohen, 2019). Despite having a top
agricultural research community, China has yet to release any formal regulation decisions on
how it will treat gene edited crops (Cohen, 2019). Most researchers believe that even though
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China strictly regulates the import of genetically modified crops, it will soon side with the USDA
in allowing gene edited crops as long as they contain no foreign DNA (Cohen, 2019). One
indication of this regulatory decision is the country’s recent purchase of Syngenta, one of the
world’s largest agribusinesses, which has an impressive CRISPR team (Cohen, 2019).
Additionally, China may be pressured to support CRISPR agriculture products because,
according to Dr. Li Jiayang, China must “feed 1.4 billion people with very limited natural
resources” (Cohen, 2019). In other words, the country needs to maximize its resources by using
pest and weather resistant crops to increase overall agricultural yield. Some experts have
predicted that China is strategically waiting to release regulatory approval until state-owned
companies such as Syngenta have products ready for market (Cohen, 2019). Even though no
official regulations have been enacted, Gao and other researchers claim that once it happens,
their CRISPR crops will be ready to release within months (Cohen, 2019).
In addition to investing in crop applications of CRISPR, China is also developing gene
edited food animals (Cohen, 2019). For example, researchers are working to improve the pork
industry (Cohen, 2019). In 2017, Dr. Zhao Jianguo and his team were successful in restoring a
gene for a protein that helps form brown fat (Cohen, 2019). This is significant because this gene
allowed newborn pigs to retain heat, thereby avoiding hypothermia and loss of product, and
producing leaner meat (Cohen, 2019). Other teams have shown promising results in speeding the
growth rate of pigs and even making them resistant to several devastating diseases that would
otherwise significantly slow production (Cohen, 2019). Overall, though China has made no
official decisions regarding the regulation of CRISPR in agriculture, geneticists there and around
the world are confident that the use of gene edited crops and food animals will soon be approved
for consumption (Cohen, 2019).
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By comparison, as a result of Dr. He Jiankui’s shocking disregard for the ban on human
embryonic CRISPR experiments, China has put forth strict regulations on human applications of
this technology (Normile, 2019). These regulations now label experiments including but not
limited to “ gene editing, the transfer of genes or attempts to regulate gene expression, the use of
stem cells” as “high-risk” (Normile, 2019). These types of experiments now require individual
approval by the State Council and informed consent of all participants (Normile, 2019).
Additionally, proposals are subject to rejection if there are any issues with funding or conflict of
interest (Normile, 2019). Even though these regulations may slow research in human
applications of CRISPR, most researchers have had a positive response (Normile, 2019). Many
are glad to have more clarity on where the Chinese government stands, and want to avoid a
repeat of the chaotic backlash caused by Dr. He Jiankui’s research (Normile, 2019). The overall
trend in China, it seems, is that they are focusing their research efforts on the agricultural
applications of CRISPR. This is wise for a number of reasons, including lower-risk research,
their limited natural resources, and easier ability to implement and profit from agricultural uses
of this biotechnology.

Consequences for International Trade
Looking forward, it is important to consider the how conflicting regulations on gene
editing may affect international trade. To evaluate this emerging issue, we can use the trade of
genetically modified organisms as a framework example. In 2001, the U.S. Government
Accountability Office released a report entitled “Concerns Over Biotechnology Challenge U.S.
Agricultural Exports”. This report summarized the conflicting regulations of GMOs between the
United States and the European Union, emphasized which crop products would be most affected,
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and described the potential challenges the U.S. would face in exporting GMO products
(Accountability Office, 2001). Similar to the current regulations facing CRISPR and other geneedited products, the United States was a leading entity in genetically modified crops, while the
European Union was strictly against their production and import (Accountability Office, 2001).
One major problem about exporting food products in that growing biotechnology age, was
“traceability” (Accountability Office, 2001). Traceability was a policy supported by the EU that
required documentation following GMOs throughout their production process (Accountability
Office, 2001). Essentially, this would mean that every product that is or contains a biotechnology
ingredient is subject to the strict regulations (Accountability Office, 2001). If this same policy is
applied to gene-edited products, it will have a major impact on trade. Not only would high oleic
soybean oil be restricted, but also any products, such as margarine, containing this oil would also
be restricted. This could lead to reduced export profits and less overall trade with the European
Union (Accountability Office, 2001). Also, in the case of GMOs, the only way the European
Union would allow trade was if the “natural” and GMO products were kept entirely separate
throughout production (Accountability Office, 2001). Given the structure of the production
system in the United States, this was not a reasonable request (Accountability Office, 2001).
Corporations were strongly against this request because, according to them, “any regulatory
measure that would ultimately lead to segregation or traceability would raise handling costs and
potentially undermine the efficiency and competitiveness of this system” (Accountability Office,
2001).
However, with gene-edited crops and products, regulation gets even more complex. As
mentioned previously, the genetic changes made using CRISPR are simply insertions or
deletions that could occur naturally with evolution, though CRISPR is targeted for selective
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advantages, and occurs at a much faster rate (Gao, 2018). Because of this, it is currently virtually
impossible to detect whether a mutation in DNA is a result of natural evolution, or CRISPR
manipulation (Gao, 2018). This brings up the issue of how the European Union will go about
enforcing its strict biotechnology regulations. There is no efficient way to test these products, so
how can the EU keep all CRISPR-edited foods out of their market? The current answer is that
European Union has no true way to enforce their regulations, and many gene-edited agricultural
products will likely become available in member countries despite restriction efforts. While the
United States may be worried about loss of trade products, European researchers are worried
about the effect these regulations will have on plant biotechnology in their countries (Stokstad,
2018). Instead of being a financially affordable production method for all scales of farms, the
expensive regulatory costs in Europe will cause gene-edited crops to only be possible for large
companies (Stokstad, 2018). This process is expected to cost around $35 million, which is much
too high for universities, nonprofits, and other small operations (Stokstad, 2018). Overall, the
conflicting regulations on biotechnology will have consequences for international trade that are
yet to be determined, but based on the framework of genetically modified organisms, these
regulations will probably lead to decreased profits and difficulty enforcing policies.

Conclusions
In general, though this revolutionary gene editing system faces mechanistic and
regulatory limitations, it has great potential to change the agriculture industry. This technology
provides opportunity for increased nutritional value, decreased food waste, and more efficient
and economic food production. For countries such as China, CRISPR food production offers the
potential benefit of overcoming limited natural resources and feeding their continuously growing
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population. Most of the mechanistic challenges are related to the specificity and efficiency of the
CRISPR-Cas system. It is important to remember that this system is already the most advanced
gene editing technology yet, and even so, scientists are constantly working to make
improvements. Though some political entities are resistant to CRIPSR agricultural products,
much of the world powers seem to embrace its potential. Other technologies such as RNA
editing are emerging in this field, and are hoped to have advantages such as reversible and
transient effects (Katrekar et al., 2019). Despite the possible advantages they hold, where they
may be reduced risk in human health applications, these technologies will likely face all the same
issues as CRISPR and gene editing, from off-target effects to regulatory set-backs. For this
reason, CRISPR is still the foremost biotechnology, as it is the most advanced, developed, and
ready for market. There is still a lot that remains to be seen about this technology, including the
public’s opinion, official regulation policies, and international trade effects. Overall, the
CRISPR-Cas system is very promising for significant improvements in food production and
sustainability.
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